EI
INSY

EAM Investors’s Insys Therapeutics, Inc. INSY Stock Holding History

EAM Investors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-224,673
Closed -$2.62M – 384
2013
Q3 		$2.62M Buy
+224,673
New +$1.84M 0.52% 37

Other funds holding INSY

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

EAM Investors's INSY Position: Q4 2013 in Review

EAM Investors sold out of Insys Therapeutics, Inc. (INSY) in Q4 2013, closing a stake of 224,673 shares — an estimated $2.62M sold.

EAM Investors first reported a position in INSY in Q3 2013 and held it in 1 quarter. The position peaked at $2.62M in Q3 2013. 86 funds tracked by Wall St. Rank hold INSY as of Q4 2013.

  • EAM Investors reported no remaining Insys Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • EAM Investors sold 224,673 Insys Therapeutics, Inc. shares in Q4 2013, an estimated $2.62M.
  • EAM Investors first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • EAM Investors's Insys Therapeutics, Inc. position peaked at $2.62M in Q3 2013.
  • 86 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2013.

Based on EAM Investors's 13F filing for Q4 2013, filed 14 Feb 2014.